Compare Mesoblast Limited (MESO) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Okta, Inc. — how do they compare? Mesoblast Limited trades at $14.06 (market cap $1.75B), while Okta, Inc. trades at $222.89 (market cap $38.50B). The key difference: Okta, Inc. is far larger — about 22× Mesoblast Limited's market cap, and Okta, Inc. is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Okta, Inc. for 44 Days on average.
| MESO | OKTA | |
|---|---|---|
Market Cap | $1.75B | $38.50B |
Volume | 239,027 | 2,479,621 |
Sector | Health | Technology |
52-Week High | $20.96 | $220.21 |
52-Week Low | $13.19 | $62.93 |
Typical Hold Time | 14 Days | 44 Days |
Enterprise Value | $1.83B | $36.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
OKTA trades at $218.00, down slightly by 0.31% on the day, with a bullish technical signal from moving averages and strong quarterly earnings beats. The company reported a net income of $28 million in 2025, marking a significant turnaround from previous losses, while revenue grew to $2.61 billion. Recent news highlights its AI agent security initiatives, including the Blueprint Alliance unveiled at Oktane 2026.
Outlook remains positive with robust analyst support (73.58% buy ratings) and a consensus price target of $201.30, though high valuation ratios and overbought RSI readings pose near-term risks. Long-term growth is supported by identity management demand and AI positioning, but competition and execution challenges are key investor considerations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
